Search PubMed⌕ Search

Biomedical subjects

O Baadsgaard

Publications and source records attributed to O Baadsgaard.

96 records · Page 6Linked to original sources

Cyclosporine A.

Explore the source record for details and available documents.

Administration, Oral↗

Superantigen Staphylococcal enterotoxin B induces release of IL-1beta in human epidermis.

Lesional skin in patients with inflammatory skin diseases is often colonized with Staphylococcus aureus, which is capable of releasing superantigens. We therefore studied whether application of superantigen on the skin led to release of cytokines, especially IL-1beta. Suction blisters were raised on vehicle- and superantigen-treated skin and IL-1beta protein levels measured in suction blister fluid and supernatant from blister roofs. In all volunteers studied, application of the superantigen Staphylococcal enterotoxin B led to increased release of IL-1beta protein from suction blister roofs (n=7). In contrast, we did not detect any difference in IL-1beta in the blister fluid (n=5). IL-1beta is known as a mediator of inflammation, and the increase in IL-1beta may be involved in the aggravation of inflammatory skin diseases seen following Staphylococcus aureus colonization.

Adult↗

Levels of enzymatic antioxidants activities in mononuclear cells and skin reactivity to sodium dodecyl sulphate.

Chemical irritants are able to produce several biological modifications of the skin, including the direct or indirect production of cytokines and reactive oxygen species leading to an inflammatory reaction. This report examines the existence of a possible correlation between the skin sensitivity to the irritant sodium dodecyl sulphate (SDS) and the activity of the enzymatic antioxidants. In twenty-three healthy subjects the evaluation of the epidermal and peripheral blood mononuclear cells (PBMCs) activities of Superoxide Dismutase (SOD) and Catalase (Cat) demonstrate a significant correlation (r= 0,85 and p< 0,005 for SOD, and r= 0,87 and p< 0,0001 for Cat). Based on this result, on a further group of normal subjects (n=13) we studied the link between the threshold dose of skin reactivity to SDS and the activities of the enzymatic antioxidants in PBMCs. The degree of skin modification induced by SDS, applied at different concentrations for 24 hrs, was determined by means of Trans Epidermal Water Loss (TEWL), Erythemal Index or by Visual Score (VS). The minimal dose of the irritant capable of inducing skin modifications, was significantly correlated with SOD (r=0,77) and Cat (r=0,81) activities in PBMCs, and the modification of TEWL or EI were inversely correlated with levels of antioxidants in PBMCs (r=-0,62 for SOD and r=-0,66 for Cat). Our results indicate that the skin reactivity to irritants can be modulated by the levels of antioxidants, and suggest a possible therapeutical approach in preventing irritant contact dermatitis.

Adult↗

Bronchodilator effects of terbutaline and theophylline alone and in combination in patients with chronic obstructive lung disease.

Thirteen patients with severe partially reversible chronic obstructive lung disease received long-term treatment with a sustained-release preparation of theophylline and a beta 2-agonist (terbutaline) alone and in combination. Combination therapy induced significantly greater bronchodilation than treatment with terbutaline alone in the recommended dose. In 9 out of 13 patients the peak flows were higher during combination therapy than during theophylline treatment alone, but this did not reach statistical significance. Only mild side effects were observed.

Adult↗

Some adverse effects of disulfiram in the treatment of nickel-allergic patients.

A retrospective follow-up study is reported of 58 women and 3 men with nickel allergy and hand eczema, of at least 4 months duration, treated with 50 to 400 mg disulfiram per day for 4 to 56 weeks. 2 patients were given 2 treatment series, making a total of 63 treatment series. 11 patients (20%) developed biochemical evidence of hepatotoxicity. 5 of them developed clinical evidence of hepatitis, which, for 4, was verified by liver biopsy. The patients with hepatotoxcity were significantly older than those who did not have this side effect. No correlation could be seen between the cumulative or maximum dose of disulfiram, the duration of the therapy and whether or not the patients showed evidence of hepatotoxicity. In 29 treatment series the dermatitis healed, while improvement was seen in 19 and no change in 15. There was no difference in the results whether maximum daily doses of 50, 200 or 400 mg were given. Follow-up examinations showed that the eczema recurred within a month after termination of therapy in 50% of the patients who improved during disulfiram therapy. Recurrence was seen within 6 months for another 40% of the patients.

Adolescent↗